Overview

Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open label study to evaluate the efficacy and safety of neoadjuvant pyrotinib in early breast cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
RenJi Hospital
Treatments:
Cisplatin
Paclitaxel
Trastuzumab